352 related articles for article (PubMed ID: 25480661)
1. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
5. Removing a hair of doubt about BRAF targeting.
Kreitman RJ
Blood; 2015 Feb; 125(8):1199-200. PubMed ID: 25700421
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutations in hairy-cell leukemia.
Tiacci E; Trifonov V; Schiavoni G; Holmes A; Kern W; Martelli MP; Pucciarini A; Bigerna B; Pacini R; Wells VA; Sportoletti P; Pettirossi V; Mannucci R; Elliott O; Liso A; Ambrosetti A; Pulsoni A; Forconi F; Trentin L; Semenzato G; Inghirami G; Capponi M; Di Raimondo F; Patti C; Arcaini L; Musto P; Pileri S; Haferlach C; Schnittger S; Pizzolo G; Foà R; Farinelli L; Haferlach T; Pasqualucci L; Rabadan R; Falini B
N Engl J Med; 2011 Jun; 364(24):2305-15. PubMed ID: 21663470
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
10. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.
Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B
Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307
[TBL] [Abstract][Full Text] [Related]
11. Genomics of Hairy Cell Leukemia.
Tiacci E; Pettirossi V; Schiavoni G; Falini B
J Clin Oncol; 2017 Mar; 35(9):1002-1010. PubMed ID: 28297625
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
13. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
15. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
16. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
18. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
